Contineum Therapeutics stock
CTNMNASDAQContineum Therapeutics, Inc., HealthcareISIN US21217B1008
35Score 35 out of 100, Weak
Price and trend
36 / 100
Price history
−15% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 27% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 63).
The price is 44% below its 52-week high. Largest decline in 3 years: 84% (July 2024 to May 2025).
Chart figures for advanced users
- SMA 50$11.43
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$13.42
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)63
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.08
- The lowest closing price of the last twelve months.
- Resistance$17.57
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Contineum Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $375.46M, is number 263 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 35 out of 100 (Weak): rank 633 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $262.9M, financial debt $8.25M.Stability 69
Weaknesses
- Loss-makingLoss of $59.98M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$55.54M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 81% a year over the last 12 months.Stability 69
The score is held back by fundamentals and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 4 Mar 2027in 112 days
- Last reported
- 3 Nov 2026EPS reported −$0.49 (expected −$0.45)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 5.1% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$1.79−4.5%
- Revenue
- $4.29M0.0%
- Earnings per share
- −$2.10−5.1%
- Revenue
- $2.2M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $1.1M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Stengone Carmine N.Sale
8 Sept 2026, CEO and President
- Shares
- 2,500
- Price
- $16.46
- Value
- $41,142
- Stengone Carmine N.Sale
3 Aug 2026, CEO and President
- Shares
- 2,500
- Price
- $16.01
- Value
- $40,029
- Lorrain Daniel S.Sale
9 Jul 2026, Chief Scientific Officer
- Shares
- 25
- Price
- $16.00
- Value
- $400
Show 6 more
- Stengone Carmine N.Sale
8 Jul 2026, CEO and President
- Shares
- 2,500
- Price
- $16.00
- Value
- $40,000
- Lorrain Daniel S.Sale
1 Jul 2026, Chief Scientific Officer
- Shares
- 8,353
- Price
- $15.84
- Value
- $132,290
- Lorrain Daniel S.Sale
30 Jun 2026, Chief Scientific Officer
- Shares
- 28,826
- Price
- $16.04
- Value
- $462,288
- Watkins TimSale
30 Jun 2026, CMO & Head of Development
- Shares
- 10,833
- Price
- $16.02
- Value
- $173,590
- Stengone Carmine N.Sale
30 Jun 2026, CEO and President
- Shares
- 10,000
- Price
- $16.01
- Value
- $160,080
- Lorrain Daniel S.Sale
1 Jun 2026, Chief Scientific Officer
- Shares
- 4,170
- Price
- $13.16
- Value
- $54,862
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Contineum Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 35
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Tectonic TherapeuticTECX $429.3M34
- RezoluteRZLT $426.45M37
- Puma BiotechnologyPBYI $417.09M61
- Lyell ImmunopharmaLYEL $414.51M33
- CorMedixCRMD $413.1M59
- X4 PharmaceuticalsXFOR $408.67M37
- ARS PharmaceuticalsSPRY $397.09M33
- NeurogeneNGNE $396.64M34
ETFs that hold Contineum Therapeutics
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.02% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 4 Apr 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.